A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
- Status
- recruiting
- Phase
- Phase 3
- Institution
- Cybin IRL Limited
- Principal investigator
- Clinical Development
- Start date
- 2024-12-17
- End date
- 2026-09-01
- Registry ID
- NCT06564818
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.